nootropic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
== Medical uses == Beta blockers are utilized in the treatment of various conditions related to the heart and vascular system, as well as several other medical conditions. Common heart-related conditions for which beta blockers are well-established include angina pectoris, acute coronary syndromes, hypertension, and arrhythmias such as atrial fibrillation and heart failure. They are also used in the management of other heart diseases, such as hypertrophic obstructive cardiomyopathy, mitral valve stenosis or prolapse, and dissecting aneurysm. Additionally, beta blockers find applications in vascular surgery, the treatment of anxiety states, cases of thyrotoxicosis, glaucoma, migraines, and esophageal varices.
== Research == 1999: Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. 2001, June: Results from ARMADA, a double-blind, placebo-controlled clinical trial involving 271 patients with active rheumatoid arthritis, despite treatment with methotrexate, are announced. Results show that 50% of patients demonstrate a 50% improvement in their American College of Rheumatology (ACR) score. 2002: Broke ground on a new biologics manufacturing facility. 2002: Adalimumab results from five separate trials show that it is effective at reducing signs and symptoms of rheumatoid arthritis, with rapid onset of action and sustained efficacy. Adalimumab was safe and effective when given alone or in combination with methotrexate (MTX) as a subcutaneous injection. 2002: Humira approved by the US Food and Drug Administration (FDA) for treatment of rheumatoid arthritis. 2003: Humira made available for the treatment of rheumatoid arthritis and continued clinical studies for additional indications. 2005: Humira made available for the treatment of psoriatic arthritis. Exceeded US$1 billion in annual sales for the first time. 2005: Japanese company Eisai submits new drug application to make adalimumab (D2E7) available for the treatment of rheumatoid arthritis in Japan. 2006: Submitted Humira for approval for the treatment of Crohn's disease. Approved for the treatment of ankylosing spondylitis. Exceeded US$2 billion in annual sales. 2007: Humira approved for the treatment of Crohn's disease in the United States.
The military base was now ostensibly renamed for Roland L. Bragg, a previously obscure soldier who served in World War II. In a meeting before the Ukraine Defense Contact Group at NATO headquarters, he opposed NATO membership for Ukraine and said that returning Ukraine's borders prior to the annexation of Crimea by Russia was "unrealistic". The Department of Defense invited Jack Posobiec, an alt-right political activist to accompany Hegseth, according to The Washington Post. Hegseth moderated his comments the following day, stating that it would be possible for Ukraine to join NATO given Trump's discretion. In February 2025, Hegseth ordered officials within the Department of Defense to reduce funding on most initiatives and began a purge from within the department, firing three top judge advocate generals and Lisa Franchetti, the chief of naval operations. Hegseth stated that "we want lawyers who give sound constitutional advice" rather than "roadblocks to anything". In March, he ordered US Cyber Command to halt offensive operations against Russia, in an apparent effort to encourage Russian president Vladimir Putin to negotiate an end to the Russo-Ukrainian War.
Sources: en.wikipedia.org
== History == Cold storage companies began to appear when food preservation using ice became commercialized. Ice was farmed from lakes during the winter, and stored, surrounded by straw to insulate it, so that it could be used well into early summer. Ice houses and ice warehouses began to appear as part of the ice trade, and blocks of ice were sold for domestic icebox use and for commercial use in cold storage. In the decades of the 1880s through 1910s, mechanical refrigeration and freezing gradually but increasingly displaced natural ice in this trade. Then in 1922, Clarence Birdseye founded the modern frozen food industry, by pioneering fast freezing (now called blast freezing), based on low temperature freezing of fish practiced by Inuit in Arctic regions.
=== Re-creation mount === Re-creation mounts are accurate life-size representations of either extant or extinct species that are created using materials not found on the animal being rendered. They utilize the fur, feathers, and skin of other species of animals. According to the National Taxidermy Association: "Re-creations, for the purpose of this [competition] category, are defined as renderings which include no natural parts of the animal portrayed. A re-creation may include original carvings and sculptures. A re-creation may use natural parts, provided the parts are not from the species being portrayed. For instance, a re-creation eagle could be constructed using turkey feathers, or a cow hide could be used to simulate African game". A famous example of a re-creation mount is a giant panda created by taxidermist Ken Walker that he constructed out of dyed and bleached black bear fur.
The class of nitazene opioids is defined chemically by the presence of the benzimidazole core structure and pharmacologically by μ opioid agonism. Nitazenes are benzimidazoles that are substituted with a dialkylaminoethyl group at the 1-position, in the 2-position with a substituted benzyl group and often in the 5-position, usually with a nitro group but sometimes with other substitutions. Compounds substituted in the 6-position are less effective, while the 4- or 7-substituted compounds are not analgesically active. Analgesically active nitazenes are also usually substituted in the para-position of the benzyl group, and only rarely in the ortho or meta positions. At the methylene linker, a methyl or an amide group is tolerated stereospecifically by the target receptor, and this carbon can also be replaced by CH2CH2, S, or NCH3 with reduced but in some cases still significant activity. Nitazenes are structurally unrelated to most other opioids, but have structural similarity to benzimidazole derivatives from the orphine group, as well as to viminol and its analogues. The compounds are derived from the historical prototype 1-(β-diethylaminoethyl)-2-benzylbenzimidazole (desnitazene). The replacement of the N,N-dialkylamino unit by pyrrolidinyl or piperidinyl, which is found in nitazepyne and nitazepipne compounds, falls into the spectrum of designer drugs. Substitution of the benzyl for thienylmethyl, pyridylmethyl, α-napthylmethyl or styryl has a potency-reducing effect.
Sources: en.wikipedia.org
The cars were cleaned with hot water or steam. Depending on the cargo, the cars might have undergone four hours of "pre-cooling" before loading, which entailed blowing in cold air through one ice hatch and allowing the warmer air to be expelled through the other hatches. The practice, dating back almost to the refrigerator car's inception, saved ice and resulted in fresher cargo. The cars' ice bunkers were filled, either manually from an icing dock, via mechanical loading equipment, or (in locations where demand for ice was sporadic) using specially designed field icing cars. The cars were delivered to the shipper for loading, and the ice was topped off. Depending on the cargo and destination, the cars may have been fumigated. The train would depart for the eastern markets. The cars were re-iced in transit approximately once a day. Upon reaching their destination, the cars were unloaded. If in demand, the cars would be returned empty to their point of origin. If not in demand, the cars would be cleaned and possibly used for a dry shipment.
=== 3D graphene === In 2013, a three-dimensional honeycomb of hexagonally arranged carbon was termed 3D graphene, and self-supporting 3D graphene was also produced. 3D structures of graphene can be fabricated by using either CVD or solution-based methods. A 2016 review by Khurram and Xu et al. provided a summary of then-state-of-the-art techniques for fabrication of the 3D structure of graphene and other related two-dimensional materials. In 2013, researchers at Stony Brook University reported a novel radical-initiated crosslinking method to fabricate porous 3D free-standing architectures of graphene and carbon nanotubes using nanomaterials as building blocks without any polymer matrix as support. These 3D graphenes (all-carbon) scaffolds/foams have applications in several fields such as energy storage, filtration, thermal management, and biomedical devices and implants. Box-shaped graphene (BSG) nanostructure appearing after mechanical cleavage of pyrolytic graphite was reported in 2016. The discovered nanostructure is a multilayer system of parallel hollow nanochannels located along the surface and having quadrangular cross-section. The thickness of the channel walls is approximately equal to 1 nm.
==== De Novo synthesis ==== The de novo biosynthesis of arginine in humans begins with glutamine. This compound is deaminated to glutamic acid and subsequently converted to glutamate-5-semialdehyde. Transamination of a second glutamic acid molecule produces ornithine, which enters the urea cycle.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.